Carregant...
Would Tirofiban Have Been Shown Non-Inferior to Abciximab Had the TENACITY Trial Not Been Terminated for Financial Reasons?
OBJECTIVES: To investigate whether tirofiban would have been non-inferior to abciximab had the trial completed enrollment, and we place the termination of this trial in a broader research ethics context. BACKGROUND: TENACITY was terminated by the sponsor for financial reasons. At the time, event rat...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4156852/ https://ncbi.nlm.nih.gov/pubmed/23379785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1540-8183.2013.12020.x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|